Senju Pharmaceutical Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Pharma Corporation

Yoshiko Takayama

Jun Inoue

Mitsuyoshi Azuma

Masayoshi Uehata

Yukuo Yoshida

Yoshikuni Nakamura

The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye. 

Agent for repairing corneal sensitivity containing amide compound

The present invention provides a visual function disorder improving agent containing a compound having Rho kinase inhibitory activity, particularly (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, as an effective component. This agent has axon of the retinal ganglion cellal extension promoting action and optic nerve cell regeneration promoting action, and is useful for the treatment of a visual function disorder associated with various eye diseases caused by damage, defects, degeneration and the like in the retinal or optic nerve.

Visual function disorder improving agents

Corneal perception recovery drug containing amide compound

Growing community of inventors

Kobe, Japan

Yoshiko Takayama